Progress in chemoprevention of breast cancer

Critical Reviews in Oncology/Hematology

Volumn 49, Issue 2, 2004, Pages 109-117

  Serrano, Davide ^a   Perego, Elisa ^b   Costa, Alberto ^b   Decensi, Andrea ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b IRCCS   (Italy)

Author keywords

Biomarker; Breast neoplasms; Chemoprevention; Clinical trial; IGF I; Tamoxifen

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; COLECALCIFEROL DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER; ESTROGEN; FENRETINIDE; GESTAGEN; HISTONE DEACETYLASE INHIBITOR; HORMONE; N (4 CARBOXYPHENYL)RETINAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; RECEPTOR BLOCKING AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTHRALGIA; BLEEDING; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ENDOMETRIUM CANCER; FRACTURE; GENE MUTATION; GENE OVEREXPRESSION; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; META ANALYSIS; MUSCULOSKELETAL DISEASE; ONCOGENE; OSTEOPOROSIS; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; VASOMOTOR DISORDER;

EID: 0842328582     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00157-4     Document Type: Review

References (39)

1. Fisher B., Costantino J.P., Wickerham D.L.et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1998;1371-1388.
2. Fisher B., Dignam J., Wolmark N.et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 353:1999;1993-2000.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
4. Lippman S.M., Lee J.J., Sabichi A.L.et al. Cancer chemoprevention: progress and promise. J. Natl. Cancer Inst. 90:1998;1514-1528.
5. O'Shaughnessy J.A., Kelloff G.J., Gordon G.B.et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res. 8:2002;314-346.
6. Kelloff G.J., Boone C.W., Crowell J.A.et al. Risk biomarkers and current strategies for cancer chemoprevention. J. Cell Biochem. Suppl. 25:1996;1-14.
7. Armstrong K., Eisen A., Weber B. Assessing the risk of breast cancer. N. Engl. J. Med. 342:2000;564-571.
8. Powles T., Eeles R., Ashley S.et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 352:1998;98-101.
9. Veronesi U., Maisonneuve P., Costa A.et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 352:1998;93-97.
10. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24.
11. Veronesi U., Maisonneuve P., Sacchini V., Rotmensz N., Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet. 359:2002;1122-1124.
12. Cuzick J., Powles T., Veronesi U.et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 361:2003;296-300.
13. Gail M.H., Costantino J.P., Bryant J.et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl. Cancer Inst. 91:1999;1829-1846.
14. Cummings S.R., Eckert S., Krueger K.A.et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. J. Am. Med. Assoc. 281:1999;2189-2197.
15. Johnston C.C.J., Bjarnason N.H., Cohen F.J.et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern. Med. 160:2000;3444-3450.
16. Cauley J.A., Norton L., Lippman M.E.et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 65:2001;125-134.
17. Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. 87:1995;645-651.
18. Decensi A., Bonanni B., Guerrieri-Gonzaga A.et al. Biologic activity of tamoxifen at low doses in healthy women. J. Natl. Cancer Inst. 90:1998;1461-1467.
19. Johnston S.R., Haynes B.P., Sacks N.P.et al. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer. Breast Cancer Res. Treat. 28:1993;241-250.
20. Guerrieri-Gonzaga A., Baglietto L., Johansson H.et al. Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiol. Biomarkers Prev. 10:2001;967-970.
21. Breuer B., Wallenstein S., Anderson R. Effect of tamoxifen on bone fractures in older nursing home residents. J. Am. Geriatr. Soc. 46:1998;968-972.
22. Decensi A., Robertson C., Viale G.et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J. Natl. Cancer Inst. 95:2003;779-790.
23. Khan S.A., Rogers M.A., Khurana K.K., Meguid M.M., Numann P.J. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J. Natl. Cancer Inst. 90:1998;37-42.
24. Huang W.Y., Newman B., Millikan R.C., Schell M.J., Hulka B.S., Moorman P.G. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am. J. Epidemiol. 151:2000;703-714.
25. Decensi A., Robertson C., Rotmensz N.et al. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group. Br. J. Cancer. 78:1998;572-578.
26. Chang J., Powles T.J., Ashley S.E.et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann. Oncol. 7:1996;671-675.
27. Guerrieri-Gonzaga A., Galli A., Rotmensz N., Decensi A. The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives. Ann. N. Y. Acad. Sci. 949:2001;113-122.
28. The ATAC (Arimidex Tamoxifen Alone or in Combination) Trialist's Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
29. Costa A., Formelli F., Chiesa F., Decensi A., De Palo G., Veronesi U. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res. 54:1994;2032s-2037s.
30. Moon R.C., Thompson H.J., Becci P.J.et al. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. 39:1979;1339-1346.
31. Favoni R.E., de Cupis A., Bruno S.et al. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Br. J. Cancer. 77:1998;2138-2147.
32. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J. Natl. Cancer Inst. 87:1995;1655-1657.
33. Mehta R.G., Moon R.C., Hawthorne M., Formelli F., Costa A. Distribution of fenretinide in the mammary gland of breast cancer patients. Eur. J. Cancer. 27:1991;138-141.
34. Veronesi U., De Palo G., Marubini E.et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. 91:1999;1847-1856.
35. Decensi A., Johansson H., Miceli R.et al. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer. Cancer Epidemiol. Biomarkers Prev. 10:2001;1047-1053.
36. Narod S.A., Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr. Opin. Obstet. Gynecol. 14:2002;19-26.
37. King M.C., Wieand S., Hale K.et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. J. Am. Med. Assoc. 286:2001;2251-2256.
38. Chan K.C., Knox W.F., Gee J.M.et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res. 62:2002;122-128.
39. Davies G., Martin L.A., Sacks N., Dowsett M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann. Oncol. 13:2002;669-678.